{"entity":{"id":"nct02793583","kind":"trial","name":"Study to Assess the Efficacy and Safety of Ublituximab + Umbralisib With or Without Bendamustine and Umbralisib Alone in Patients With Previously Treated Non-Hodgkins Lymphoma","aka":[],"tldr":"A phase 2/3 trial of Umbralisib and Bendamustine in Diffuse large B-cell lymphoma, Follicular lymphoma, Marginal zone lymphoma and Mantle cell lymphoma, run by TG Therapeutics, Inc., recorded as terminated on the registry.","summary":"Study to Assess the Efficacy and Safety of Ublituximab + Umbralisib With or Without Bendamustine and Umbralisib Alone in Patients With Previously Treated Non-Hodgkins Lymphoma is a phase 2/3 interventional study registered as NCT02793583 by TG Therapeutics, Inc., with 710 participants recorded, started 2016-05-25 and due to reach its primary completion in 2022-05-31. Interventions recorded: Ublituximab, Umbralisib, Bendamustine. Conditions recorded: Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, Marginal Zone Lymphoma, Mantle Cell Lymphoma, Small Lymphocytic Lymphoma.\n\nLinked to the drug Umbralisib because the registry names it among its interventions and Diffuse large B-cell lymphoma, Follicular lymphoma, Marginal zone lymphoma and Mantle cell lymphoma among its conditions. Registry record only: no result has been read by an editor.","asOf":"2026-09-22","links":[{"label":"ClinicalTrials.gov NCT02793583","url":"https://clinicaltrials.gov/study/NCT02793583"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["dlbcl","follicular-lymphoma","marginal-zone-lymphoma","mantle-cell-lymphoma"],"sections":[],"technologies":[],"targets":[],"drugs":["umbralisib","bendamustine"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT02793583","phase":"2/3","setting":"A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + Umbralisib With or Without Bendamustine and Umbralisib Alone in Patients With Previously Treated Non-Hodgkin's Lymphoma","sponsor":"TG Therapeutics, Inc.","participation":[{"nct":"NCT02793583","source":"https://clinicaltrials.gov/study/NCT02793583","fetchedAt":"2026-10-07T16:52:51.246Z","studySha256":"9ae3c87ed6f651291a0eff041bc7bedad1c5e40553556c8f42d02cc6824062f6","overallStatus":"TERMINATED","lastUpdatePosted":"2022-07-21","whyStopped":"Strategic/Business Decision","leadSponsor":"TG Therapeutics, Inc.","collaboratorCount":0,"minimumAge":"18 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":710,"enrolmentType":"ACTUAL","siteCount":168,"recruitingSiteCount":0,"countries":["Australia","Israel","Italy","Poland","Slovakia","South Korea","Spain","United Kingdom","United States"]}],"started":"2016-05-25","startedType":"actual","enrolled":710,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct02793583/","neighbours":{"cancer":[{"id":"dlbcl","kind":"cancer","name":"Diffuse large B-cell lymphoma","route":"/cancers/dlbcl/"},{"id":"follicular-lymphoma","kind":"cancer","name":"Follicular lymphoma","route":"/cancers/follicular-lymphoma/"},{"id":"mantle-cell-lymphoma","kind":"cancer","name":"Mantle cell lymphoma","route":"/cancers/mantle-cell-lymphoma/"},{"id":"marginal-zone-lymphoma","kind":"cancer","name":"Marginal zone lymphoma","route":"/cancers/marginal-zone-lymphoma/"}],"drug":[{"id":"bendamustine","kind":"drug","name":"Bendamustine","route":"/drugs/bendamustine/"},{"id":"umbralisib","kind":"drug","name":"Umbralisib","route":"/drugs/umbralisib/"}]}}